Compared to Estimates, Steris (STE) Q3 Earnings: A Look at Key Metrics

For the quarter ended December 2025, Steris (STE) reported revenue of $1.5 billion, up 9.2% over the same period last year. EPS came in at $2.53, compared to $2.32 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $1.48 billion, representing a surprise of +1.08%. The company delivered an EPS surprise of -0.1%, with the consensus EPS estimate being $2.53.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Steris performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenues- Healthcare: $1.06 billion versus the four-analyst average estimate of $1.05 billion. The reported number represents a year-over-year change of +9%.
• Revenues- Healthcare Products- Consumables: $387.1 million versus the four-analyst average estimate of $381.88 million. The reported number represents a year-over-year change of +8.1%.
• Revenues- Healthcare Products- Capital Equipment: $272.1 million versus the four-analyst average estimate of $278.71 million. The reported number represents a year-over-year change of +6.8%.
• Revenues- Healthcare Products- Service: $404.7 million versus the four-analyst average estimate of $391.52 million. The reported number represents a year-over-year change of +11.5%.
• Revenues- Life Sciences: $145.8 million versus $148.25 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +6.9% change.
• Revenues- Applied Sterilization Technologies (AST): $286.6 million compared to the $278.6 million average estimate based on four analysts. The reported number represents a change of +11% year over year.
• Revenues- Life Sciences- Service: $36.5 million versus the three-analyst average estimate of $39.26 million. The reported number represents a year-over-year change of -0.4%.
• Revenues- Life Sciences- Capital Equipment: $33.3 million compared to the $36.67 million average estimate based on three analysts. The reported number represents a change of +7.2% year over year.
• Revenues- Life Sciences- Consumables: $75.9 million compared to the $71.77 million average estimate based on three analysts. The reported number represents a change of +10.5% year over year.
• Operating income / (loss)- Healthcare: $258.1 million versus the three-analyst average estimate of $257.71 million.
• Operating income / (loss)- Corporate and Other: $-106 million versus the three-analyst average estimate of $-103.36 million.
• Operating income / (loss)- Applied Sterilization Technologies (AST): $129.2 million versus $125.53 million estimated by three analysts on average.

View all Key Company Metrics for Steris here>>>

Shares of Steris have returned +0.6% over the past month versus the Zacks S&P 500 composite's +0.9% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

 
STERIS plc (STE): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research